A Phase I Ascending Dose Safety Study Of Intramuscular CTX0E03 In Patients With Lower Limb Ischaemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs ReN 009 (Primary)
- Indications Peripheral ischaemia
- Focus Adverse reactions
- Sponsors ReNeuron
- 23 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018.
- 23 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
- 23 Apr 2017 Status changed from recruiting to active, no longer recruiting.